0会 2023年 ,报 ,河 (以 " ")董 ,认 , ,充 2023年 : ,为 2023年 ,公 ,本 ,积 ,2023年 : (一 )2023年 1月 6日 ,公 , 2022年 2023年 ,并 (二 )2023年 4月 23日 ,公 , 2022年 2022年 2022年 2023年 ,并 ,同 (三 )2023年 8月 8日 ,公 , 2023年 2023年 ,并 ,同 (四 )2023年 10月 26日 ,召 ,审 2023年 2023年 , ,同 2023年 ,建 2023年 ,公 ,敦 ,公 ,重 ,为 (一 )监 (特 ) (以 " ")进 ,协 ,并 ,对 ,要 ,就 ,认 ,督 ,确 ,董 ,认 ,勤 ,遵 ,实 ,真 , ,向 2023年 (二 )指 ,督 , ,督 ,我 (三 )审 ,公 ,在 ,不 ,不 (四 )评 ,积 ,公 ,股 ,切 ,公 ,内 (五 )协 ,我 ,积 ,使 (特 )进 ,提 ,我 ,充 , ,恪 ,切 （此页无正文,为河南羚锐制药股份有限公司董事会审计委员会 2023 年度履 职情况报告之签字页。 ) 董事会审计委员会委员签字: 熊 伟: 潘滋润: 李 ...

2023年 (李 ) (以 " ")的 ,2023年 ,本 1号—— ,勤 ,审 ,出 ,认 ,对 ,维 ,较 ,对 ,以 2023年 : (一 )独 ,女,汉 ,1967年 7月 ,博 ,河 (二 )是 ,任 ,本 ,本 ,不 2023年 ,作 ,本 ,认 ,积 ,并 ,为 (一 )2023年 (二 )现 1、 2023年 ,公 8次 ,内 ,亲 ,积 2023年 ,公 1次 ,本 ,认 ,主 ,本 ,充 ,会 ,详 ,积 ,利 , ,没 ,为 ,2023年 , 2、 2023年 ,公 1次 2次 4次 4次 ,涵 ,我 ,均 ,帮 ,助 2023年 ,我 ,重 ;听 ,并 ,积 ;同 ,与 ,及 ,积 ,关 , ,促 ,召 ,相 ,有 · (一 )关 2023年 ,关 ,定 ,符 ,不 ,也 (二 )对 ,我 ,截 2023年 12 31日 ,公 ,亦 (三 )募 ,公 ( (四 )业 ,公 (五 )聘 ,公 (特 )为 2023年 2023年 ,并 :大 (特 )在 ,遵 ,出 ,同 , ,审 ,不 (六 )现 ,公 2022年 ,每 0。 60元 (含 )。 :公 2022年 ,综 ,符 ,不 ,有 ...

Financial Performance - Net profit attributable to shareholders of the listed company was ¥190,378,639.92, representing a year-on-year increase of 31.98%[18] - Basic earnings per share increased to ¥0.340, up 30.77% year-on-year[18] - The weighted average return on net assets rose to 6.59%, an increase of 1.09 percentage points[18] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 31.55%, primarily due to an increase in sales revenue[22] - The total profit for the period was approximately 220.82 million yuan, compared to 169.95 million yuan in the previous year[32] - The company reported a net profit of CNY 220,826,418.61 for Q1 2024, up from CNY 170,629,996.52 in Q1 2023, representing a growth of 29.4%[46] Revenue and Costs - Operating revenue for the first quarter was ¥909,046,867.70, reflecting a growth of 15.27% compared to the same period last year[18] - Total operating revenue for Q1 2024 reached CNY 909,046,867.70, an increase of 15.2% compared to CNY 788,648,249.06 in Q1 2023[46] - Total operating costs for Q1 2024 were CNY 696,497,752.04, up from CNY 622,764,688.53 in Q1 2023, reflecting a growth of 11.8%[46] Assets and Equity - Total assets at the end of the reporting period reached ¥4,981,554,316.97, an increase of 4.39% compared to the end of the previous year[5] - Shareholders' equity attributable to shareholders of the listed company was ¥2,934,067,847.86, up 5.12% from the previous year[5] - The company's total equity reached CNY 2,941,689,710.88 as of March 31, 2024, compared to CNY 2,798,696,938.00 at the end of 2023, indicating a growth of 5.1%[43] Cash Flow - Net cash flow from operating activities was ¥44,906,293.79, a decrease of 44.91% compared to the previous year[18] - The net cash flow from operating activities decreased by 44.91%, mainly due to a reduction in cash collections and an increase in payable amounts[22] - Net cash flow from operating activities for Q1 2024 was CNY 44,906,293.79, a decrease of 45% from CNY 81,521,628.54 in Q1 2023[49] - The net increase in cash and cash equivalents was -23,997,997.85, compared to an increase of 241,987,944.29 in the previous period[51] - Cash and cash equivalents at the end of the period totaled 1,466,278,009.71, down from 1,421,283,621.04 in the previous period[51] Investments and Financing - The company received government subsidies amounting to ¥2,272,384.03, which are closely related to its normal business operations[5] - Net cash flow from investing activities was -57,440,536.53, compared to 142,373,586.31 in the previous period[51] - Total cash inflow from financing activities was 8,612,408.51, while cash outflow was 20,076,857.67, resulting in a net cash flow of -11,464,449.16[51] - Cash received from borrowings was 38,792,765.60, while cash paid for debt repayment was 20,000,000.00[51] Research and Development - Research and development expenses for Q1 2024 were CNY 20,393,113.38, a decrease of 3.8% from CNY 21,205,202.59 in Q1 2023[46] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22]

河南羚锐制药股份有限公司 第九届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 河南羚锐制药股份有限公司（以下简称"公司"）第九届董事会第七次会议 于 2024 年 4 月 12 日以通讯方式发出通知,并于 2024 年 4 月 24 日上午 9:00 在河 南省新县将军路 666 号羚锐制药一楼会议室以现场及通讯相结合方式召开。会议 应到董事 9 名,实到 9 名。会议的召集和召开符合《中华人民共和国公司法》和 《河南羚锐制药股份有限公司章程》的规定。与会董事就会议议案进行了审议、 表决，形成了如下决议： 一、审议通过《2023 年度董事会工作报告》 表决结果： 9 票赞成， 0 票反对， 0 票弃权 本议案尚需提交公司 2023 年年度股东大会审议批准。 二、审议通过《2023 年度总经理工作报告》 表决结果： 9 票赞成， 0 票反对， 0 票弃权 三、审议通过《2023 年度独立董事述职报告》 证券简称：羚锐制药 证券代码：600285 公告编号： 2024-012 号 详见上海证券交易 ...

河南羚锐制药股份有限公司 审计报告 大华审字[2024]0011010913 号 (2023 年 1 月 1 日至 2023 年 12 月 31 日止 ) | | | 目 录 | 页 次 | | --- | --- | --- | --- | | 1 | 审计报告 | | 1-5 | | i í | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-95 | 安区西瓜环中路 16 导院 7 早米 12 (10) 5835 0011 传真: 86 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants（Special General Partnership） 您可使用手机"扫一扫"或进入"注册会计师行业统一监 ...

Financial Performance - The company's total revenue for 2023 reached RMB 3,311,472,606.54, representing a year-on-year increase of 10.31% compared to RMB 3,001,862,213.98 in 2022[27] - Net profit attributable to shareholders for 2023 was RMB 568,109,302.85, a 22.09% increase from RMB 465,304,594.10 in 2022[27] - The net profit after deducting non-recurring gains and losses was RMB 534,225,526.92, reflecting a 30.61% increase from RMB 409,014,562.15 in the previous year[27] - Basic earnings per share (CNY/share) increased to 1.012, up 21.05% from the previous year[30] - Diluted earnings per share (CNY/share) rose to 1.003, reflecting a 22.47% increase year-over-year[30] - The company's operating income for Q2 2023 was CNY 912,014,246.50, marking a strong performance in revenue generation[31] - The net profit attributable to shareholders for Q3 2023 was CNY 149,200,935.99, demonstrating consistent profitability across quarters[31] - The company achieved a revenue of 5,468 million yuan in the traditional Chinese medicine sector, representing a year-on-year growth of 6.5%[52] - The company achieved total revenue of 3.311 billion yuan, a year-on-year increase of 10.31%[90] - The net profit attributable to shareholders of the listed company was 568 million yuan, representing a year-on-year growth of 22.09%[90] Assets and Investments - The company's total assets as of the end of 2023 amounted to RMB 4,771,917,373.39, up 9.84% from RMB 4,344,621,675.16 in 2022[27] - The net assets attributable to shareholders reached RMB 2,791,040,844.65, which is a 9.42% increase from RMB 2,550,814,143.95 in 2022[27] - The total amount of accounts receivable increased by 31.86% to approximately ¥258.40 million, attributed to increased business revenue[125] - The company reported a significant increase in other non-current assets, rising by 107.81% to approximately ¥761.73 million, mainly due to an increase in long-term deposits[125] - The company’s short-term borrowings increased by 50.54% to approximately ¥141.22 million, primarily due to an increase in unconfirmed bill discounts[125] Research and Development - The company employed 210 R&D personnel, representing 17.13% of the total workforce[1] - The company is committed to continuous investment in R&D, with a focus on product quality standards and innovation in topical formulations[42] - The total R&D expenditure amounted to CNY 106.98 million, which is 3.23% of the operating revenue[107] - The company has increased R&D investment in the patch field, focusing on secondary development of existing products and advancing other health product R&D[145] - Major R&D projects include LR003 with an investment of ¥4,155,217.02, accounting for 0.126% of revenue, which increased by 25.68% year-on-year[157] - The company’s R&D investment accounted for 3.23% of its revenue during the reporting period[154] - The company’s R&D investment as a percentage of net assets was 3.83% during the reporting period[154] Marketing and Brand Development - The company is focusing on brand development and service quality enhancement, aiming for high-quality growth and new production capabilities[40] - The company is focusing on enhancing its brand presence through various consumer engagement activities, including themed events and advertising in high-traffic areas[44] - The company is committed to providing comprehensive health management solutions, emphasizing consumer needs and product innovation[68] - The company focuses on consumer health needs, enhancing brand strength through a "1+N" brand strategy, with sub-brands like "Two Tigers" and "Little Antelope" aimed at bone and children's health[119] - The company is enhancing its marketing network by deepening cooperation with key clients and expanding its presence in traditional and e-commerce channels[45] Production and Quality Management - The company is implementing automation upgrades in its production lines, which include the installation of visual inspection systems and electronic supervision codes, aimed at improving production efficiency and product quality[42] - The company has established a risk prevention mechanism for quality management, ensuring compliance and control throughout the production process[48] - The company is committed to improving production quality and efficiency through lean management and automation upgrades, aiming for breakthroughs in capacity release and product quality[179] Governance and Compliance - The company maintains a robust governance structure, ensuring compliance with relevant laws and regulations, and has established clear responsibilities for the board of directors and supervisory board[194] - The company has implemented effective internal control systems across various areas, including financial management and auditing, to ensure operational integrity[197] - The company has a transparent information disclosure process, with timely reporting of financial results and significant events, ensuring compliance with regulatory requirements[197] - The company’s governance practices align with the requirements of the Company Law and other relevant regulations, with no significant discrepancies noted[197] Market Trends and Future Outlook - The pharmaceutical market is expected to grow steadily due to increasing disposable income and health awareness among residents[172] - The company anticipates a more regulated industry environment due to ongoing policy adjustments in the healthcare sector[172] - The aging population is expected to drive the market for chronic disease-related medications, benefiting the company's product promotion efforts[175] - The company plans to continue expanding into potential markets to drive future growth[92] - The market for orthopedic diseases is expected to grow further, driven by an increasing number of patients and a rising demand for self-management solutions[61] Risks and Challenges - The company anticipates potential risks from policy changes, product quality management, and the high costs and uncertainties associated with new drug development[182] - The company will implement measures to mitigate cost volatility risks by diversifying procurement channels and improving inventory management[190]

独立性的相关要求。 河南羚锐制药股份有限公司董事会 二○二四年四月二十四日 河南羚锐制药股份有限公司 董事会对独立董事 2023 年度独立性情况评估的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会 就公司独立董事李慧、梅夏英、杨钧 2023 年度独立性情况进行评估并出具如下 专项意见: 经核查公司独立董事李慧、梅夏英、杨钧的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立董事 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2024-020 (五) 网络投票的系统、起止日期和投票时间。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 召开的日期时间：2024 年 5 月 20 日 14 点 00 分 召开地点：河南省新县将军路 666 号羚锐制药会议室 河南羚锐制药股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 股东大会召开日期：2024年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 20 日 至 2024 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的 ...

河南羚锐制药股份有限公司 2023 年度内部控制评价报告 河南羚锐制药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序 ...

证券代码：600285 证券简称：羚锐制药 公告编号： 2024-019 号 河南羚锐制药股份有限公司 未来三年（2024-2026 年度）股东回报规划 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为完善和健全河南羚锐制药股份有限公司(以下简称"公司") 利润分配决 策程序和监督机制，积极回报投资者，充分维护公司股东权益，引导投资者树立 长期投资和理性投资的理念，根据中国证监会《关于进一步落实上市公司现金分 红有关事项的通知》（证监发【2012】37 号）、《上市公司监管指引第 3 号—— 上市公司现金分红》（证监会公告【2023】61 号）、《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》（上证发【2023】193 号）等相关法律、 法规以及《公司章程》的规定，结合公司的实际情况，公司制订了《未来三年（2024 －2026 年度）股东回报规划》（以下简称"本规划"或"规划"），主要内容如 下： 二、规划的制定原则 一、公司制定规划考虑的因素 公司从长远、可持续发展的角度出发，综合考虑投资者的合理投资回 ...